alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
---

CERTIFICATION
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF
TITLE 18, UNITED STATES CODE)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of Title 18, United States Code), each of the undersigned officers of Dragon Pharmaceutical Inc., a Florida corporation (the "Company"), does hereby certify with respect to the Quarterly Report of the Company on Form 10-Q for the quarter ended March 31,2009 as filed with the Securities and Exchange Commission (the "Form 10-Q") that, to the best of their knowledge:

(1) the Form 10-Q fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.



|                       |  |                                                                            
|---------------------- |  | ---------------------------------------------------------------------------
|Dated: :  May 15, 2009 |  | ___/s/ Yanlin Han      __________________Yanlin Han
Chief Executive Officer
|Dated: :  May 15,2009  |  | ___/s/  Garry Wong               _______
Garry Wong
Chief Financial Officer





---
#### § 95.45 Cost and price analysis.

Some form of cost or price analysis shall be made and documented in the procurement files in connection with every procurement action. Price analysis may be accomplished in various ways, including the comparison of price quotations submitted, market prices and similar indicia, together with discounts. Cost analysis is the review and evaluation of each element of cost to determine reasonableness, allocability and allowability.
<PAGE>
 
                                                                  EXHIBIT 3.2(c)


                         AMENDMENT NO. 2 TO BY-LAWS OF
                        MARQUETTE MEDICAL SYSTEMS, INC.
                (Formerly Known as Marquette Electronics, Inc.)
                         (As Adopted November 20, 1996)



          1.   Article XI is hereby redesignated as Article XII and the
     following be and is hereby adopted as Article XI of the By-Laws, to-wit:

                                  "ARTICLE XI
                                  -----------
                             Conflicts of Interest
                             ---------------------

               1.   A Director shall be considered to have a conflict of
     interest if:

               (a) The Director has existing or potential financial or other
     interests which impair or might reasonably appear to impair their
     independent, unbiased judgment in the discharge of their responsibilities
     to the Corporation.

               (b) Directors are aware that a member of their family (which for
     the purposes of this paragraph shall be a spouse, parents, siblings,
     children, and any other relative if the latter resides in the same
     household as the Director) has such existing or potential or other
     interests.

               (c) Any organization in which the Director (or member of their
     family) is an officer,  director, employee, member, partner, trustee, or
     controlling stockholder has such existing or potential or other interests.

               2.   The following guidelines exist in cases where a real or
     perceived conflict of interest exists:

               (a) The Director shall disclose to the Board any possible
     conflict of interest at the earliest practical time.

               (b) No Director shall vote on any matter under consideration at a
     Board or Committee meeting, in which such director has a conflict of
     interest.

               (c) The minutes of such meeting shall reflect that a disclosure
     was made and that the Director having a conflict of interest abstained from
     voting.
<PAGE>
 
               (d) Any Director who is uncertain whether a conflict of interest
     may exist in any matter may request the Board or Committee to resolve the
     questions by majority vote."


          3.   This Amendment shall be known as Amendment No. 2 to the Amended
     and Restated By-Laws of Marquette Medical Systems, Inc.

          4.   In all other respects, the Amended and Restated By-Laws of
     Marquette Medical Systems, Inc., as adopted on January 8, 1996, and amended
     by Amendment No. 1 adopted May 21, 1996, shall remain in full force and
     effect.
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002   In connection with the Quarterly Report of Wizzard Software Corporation (the "Registrant") on Form 10-Q for the period ending June 30, 2010, as filed with the Securities and Exchange Commission on the date hereof (the "Quarterly Report"), we, Christopher J. Spencer, President, CEO and Treasurer and John Busshaus, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:  (1) The Quarterly Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  (2)  The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and result of operations of the Registrant.   Date:8/16/10By:/s/ Christopher J. SpencerChristopher J. SpencerChief Executive Officer and President   Date:8/16/10By:/s/ John BusshausJohn BusshausChief Financial Officer
**Exhibit 32.1**

**SECTION 1350 CERTIFICATIONS**

In connection with the Amendment No. 1 to the Annual Report of Magellan Petroleum Corporation (the “Company”) on Form 10-K/A for the period ending June 30, 2010 as filed with theSecurities and Exchange Commission on the date hereof (the “Report”), I, William H. Hastings, President and Chief Executive Officer of the Company, does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuantto Section 906 of the Sarbanes-Oxley Act of 2002, that: 

(1) The Report fully complies with therequirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 

(2) Theinformation contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. 

 

Dated: June 15, 2011
§ 110.51 Groton, Conn. The waters between an unnamed cove and Pine Island. ( a ) Beginning at a point on the shoreline of Avery Point at latitude 41°19′01.4′′, longitude 072°03′42.8′′; thence to a point in the cove at latitude 41°19′02.5′′, longitude 72°03′36.2′′; thence southeasterly to a point at latitude 41°18′56.2′′, longitude 072°03′34.2′′; thence northeasterly to latitude 41°19′02.5′′, longitude 072°03′19.2′′ thence terminating at the tip of Jupiter Point at latitude 41°19′04.4′′, longitude 072°03′19.7′′. DATUM: NAD 83
( b ) Beginning at a point on the shoreline of Pine Island at latitude 41°18′47.1′′, longitude 072°03′36.8′′; thence northerly to latitude 41°18′54.1′′, longitude 072°03′35.4′′; thence northeasterly to a point at latitude 41°19′01.2′′, longitude 072°03′19.3′′; thence terminating at a point at latitude 41°18′54.0′′, longitude 072°03′17.5′′. DATUM: NAD 83
[CGD01-97-014, 63 FR 34815, June 26, 1998, as amended by USCG-2019-0952, 88 FR 16187, Mar. 16, 2023]
National Kidney Foundation of Michigan

Chronic Disease Self-Management Education Program Grantee

1 of 2

Goals 

The overall purposes of this 3-year grant are to:

• Goal 1: Develop or expand capacity to 

significantly increase the number of 

older adults and adults with disabilities, 

particularly those in underserved 

areas/populations, who participate in 

evidence-based chronic disease selfmanagement education and selfmanagement support programs to 

empower them to better manage their 

chronic conditions.

• Goal 2: Enhance the sustainability of 

evidence-based chronic disease selfmanagement education and selfmanagement support programs 

through the implementation of robust 

sustainability strategies.

Strategies and Activities

The National Kidney Foundation of Michigan 

(NKFM) and its partners will: 

• Integrate CDSME and support programs 

into strategies for managing kidney 

health.

• Develop and strengthen referral 

pathways for CDSME and support 

programs.

• Build on current infrastructure and 

expand delivery of remote, in-person 

and digital programming

• Develop value propositions to secure 

contracts with payers.

Proposed Interventions

• Better Choices Better Health (BCBH)

• Chronic Disease Self-Management 

Program (CDSMP)

• Diabetes Self-Management Program 

(DSMP)

• Health Coaches for Hypertension 

Control (HCHC)

• Walk with Ease (WWE)

Partnerships 

To achieve the goals of the grant, NKFM will 

collaborate with the following key partners:
2 of 2

• Area Agencies on Aging 

• Ascension

• Beaumont Health

• Canary Health

• Health Alliance Plan

• Hypertension Nephrology Associates

• Michigan Association of Health Plans

• Michigan Department of Health and 

Human Services

• Michigan State University Extension

• National Kidney Foundation

• Thumb Community Health Partnership

• UnitedHealthcare Community Plan

• University of Michigan Health System

• Upper Peninsula Health Plan

• Western Wayne Family Health Centers

Anticipated Results 

The NKFM and its partners propose to achieve 

the following results: 

• Engage 868 participants that complete 

CDSME and Support programs (70% 

average completion across programs).

• Enhance collaboration and 

infrastructure for promotion, delivery, 

and availability of CDSME and support 

programs

• Establish referral pathways with health 

systems, healthcare providers, and 

community based organizations

• Secure contracts with payers for selfmanagement programs, especially for 

preventing and managing chronic 

kidney disease.

Contact:

Ann Andrews

National Kidney Foundation of Michigan

aandrews@nkfm.org

Jodi Burke

National Kidney Foundation of Michigan

jburke@nkfm.org

For more information: 

Administration for Community Living 

U.S. Department of Health and Human Services

Washington, DC 20201; 

http://www.acl.gov
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration
 Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on December 22, 1999, Lonza Riverside, 900 River Road, Conshohocken, Pennsylvania 19428, made application by renewal which was received for processing April 12, 2000, to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below: Drug
ScheduleAmphetamine (1100)
IIPhenylacetone (8501)
II
 The firm plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration. Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than August 1, 2000. Dated: May 24, 2000. John H. King, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.


[FR Doc. 00-13786  Filed 6-1-00; 8:45 am] BILLING CODE 4410-09-M
ADC TELECOMMUNICATIONS, INC.
2011 EXECUTIVE MANAGEMENT INCENTIVE PLAN
 Section 1. Establishment; Purpose
 Establishment
 Purpose
 Section 2. Administration
 Composition of the Committee
 Power and Authority of the Committee
 Qualified Performance-Based Compensation




---



##### 



(A)
    
    designate all Participants for such fiscal
year; and(B)
    
    establish the objective performance factors for
each Participant for that fiscal year on the basis of one or more of
the business criteria set forth herein.
   Section 3. Eligibility and Participation
 Eligibility
 Participation
 Employment
 2




---



##### 



Section 4. Payment of Annual Cash Bonus Awards
 General
 Payment of Annual Cash Bonus Awards
 Discretionary Reduction
 Section 5. Termination of Employment
 Termination of Employment.
 Death
 Section 6. Nontransferability
  Section 7. Taxes
  Section 8. Amendment and Termination
 Term of Plan
 3




---



##### 



Amendments to and Termination of Plan provided however
 Correction of Defects, Omissions and Inconsistencies
 Section 9. Miscellaneous
 Governing Law
 Severability
 No Trust or Fund Created
 Nature of Payments
 4
III 

110TH CONGRESS 

1ST SESSION S. RES. 273 

Expressing the sense of the Senate that the United States Postal Service 

should issue a semipostal stamp to support medical research relating 

to Alzheimer’s disease. 

IN THE SENATE OF THE UNITED STATES 

JULY 16, 2007 

Ms. MIKULSKI submitted the following resolution; which was referred to the 

Committee on Homeland Security and Governmental Affairs 

RESOLUTION 

Expressing the sense of the Senate that the United States 

Postal Service should issue a semipostal stamp to support medical research relating to Alzheimer’s disease. 

1 Resolved, That it is the sense of the Senate that the 

2 United States Postal Service should, in accordance with 

3 section 416 of title 39, United States Code— 

4 (1) issue a semipostal stamp to support medical 

5 research relating to Alzheimer’s disease; and 

6 (2) transfer to the National Institutes of Health 

7 for that purpose any amounts becoming available 

8 from the sale of such stamp. 

Æ 


ccoleman on PROD1PC69 with BILLS
Editorial Note on Part 116
Editorial Note: Nomenclature changes to part 116 appear by USCG-2008-0179, 73 FR 35012, June 19, 2008 and USCG-2010-0351, 75 FR 49410, Aug. 13, 2010.

§ 116.20 Detailed investigation. ( a ) When the Chief, Office of Bridge Programs determines that a Detailed Investigation should be conducted, the District Commander will initiate an investigation that addresses all of the pertinent data regarding the bridge, including information obtained at a public meeting held under § 116.25. As part of the investigation, the District Commander will develop a comprehensive report, termed the “Detailed Investigation Report”, which will discuss: the obstructive character of the bridge in question; the impact of that bridge upon navigation; navigational benefits derived; whether an alteration is needed to meet the needs of navigation; and, if alteration is recommended, what type.
( b ) The District Commander will forward the completed Detailed Investigation Report to the Chief, Office of Bridge Programs for review together with a recommendation of whether the bridge should be declared an unreasonable obstruction to navigation and, if so, whether an Order to Alter should be issued.
[CGD 91-063, 60 FR 20902, Apr. 28, 1995, as amended by CGD 96-026, 61 FR 33663, June 28, 1996; USCG-2013-0397, 78 FR 39174, July 1, 2013]
§ 825.119 Leave for treatment of substance abuse. ( a ) Substance abuse may be a serious health condition if the conditions of §§ 825.113 through 825.115 are met. However, FMLA leave may only be taken for treatment for substance abuse by a health care provider or by a provider of health care services on referral by a health care provider. On the other hand, absence because of the employee's use of the substance, rather than for treatment, does not qualify for FMLA leave.
( b ) Treatment for substance abuse does not prevent an employer from taking employment action against an employee. The employer may not take action against the employee because the employee has exercised his or her right to take FMLA leave for treatment. However, if the employer has an established policy, applied in a non-discriminatory manner that has been communicated to all employees, that provides under certain circumstances an employee may be terminated for substance abuse, pursuant to that policy the employee may be terminated whether or not the employee is presently taking FMLA leave. An employee may also take FMLA leave to care for a covered family member who is receiving treatment for substance abuse. The employer may not take action against an employee who is providing care for a covered family member receiving treatment for substance abuse.
Exhibit 32.2

SECTION 1350 CERTIFICATIONS

In connection with
the Annual Report of Magellan Petroleum Corporation (the Company) on Form 10-K for the period ending June 30, 2009 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Daniel J.
Samela, Chief Financial and Accounting Officer of the Company, does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of
1934; and

(2) The information contained in the Report fairly presents, in all material respects, the
financial condition and result of operations of the Company.



By:

/S/    DANIEL J.
SAMELADaniel J. SamelaChief Financial Officer and Chief Accounting Officer


October 2, 2009
# EUR-Lex - 32000R0477 - EN

Avis juridique important

*|*

# 32000R0477

**Commission Regulation (EC) No 477/2000 of 2 March 2000 fixing the guarantee threshold quantities which may be transferred to another group of varieties for the 2000 harvest in the raw tobacco sector **

*
Official Journal L 058 , 03/03/2000 P. 0005 - 0006 *

COMMISSION REGULATION (EC) No 477/2000

of 2 March 2000

fixing the guarantee threshold quantities which may be transferred to another group of varieties for the 2000 harvest in the raw tobacco sector

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Regulation (EEC) No 2075/92 of 30 June 1992 on the common organisation of the market in raw tobacco(1), as last amended by Regulation (EC) No 660/1999(2), and in particular Article 9(4) thereof,

Whereas:

(1) Article 9 of Regulation (EEC) No 2075/92 introduced production quotas for the different groups of varieties of tobacco. The individual quotas were divided between producers on the basis of the guarantee thresholds for the 2000 harvest fixed in Article 3 of Regulation (EC) No 660/1999. Under Article 9(4) of Regulation (EEC) No 2075/92 the Commission may authorise Member States to transfer parts of their guarantee threshold allocations between groups of varieties. These transfers do not give rise to additional costs between groups of varieties to the EAGGF and do not involve any increase in Member States' overall guarantee threshold allocations.

(2) This Regulation should apply as soon as possible, well before the deadline for the conclusion of cultivation contracts laid down in Article 10(1) of Commission Regulation (EC) No 2848/98 of 22 December 1998 laying down detailed rules for the application of Council Regulation (EEC) No 2075/92 as regards the premium scheme, production quotas and the specific aid to be granted to producer groups in the raw tobacco sector(3), as last amended by Regulation (EC) No 2637/1999(4).

(3) The measures provided for in this Regulation are in accordance with the opinion of the Management Committee for Tobacco,

HAS ADOPTED THIS REGULATION:

Article 1

For the 2000 harvest, in accordance with Article 22(4) of Regulation (EC) No 2848/98, Member States shall be authorised to transfer guarantee threshold quantities from one group of varieties to another in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the day of its publication in the Official Journal of the European Communities.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 2 March 2000.

For the Commission

Franz FISCHLER

Member of the Commission

(1) OJ L 215, 30.7.1992, p. 70.

(2) OJ L 83, 27.3.1999, p. 10.

(3) OJ L 358, 31.12.1998, p. 17.

(4) OJ L 323, 15.12.1999, p. 8.

ANNEX

Guarantee threshold quantities which each Member State is authorised to transfer from one group of varieties to another

>TABLE>
## p^rny teekJels©r\ iHQliertS

Uh^ RECEIVED IN COURT OF CRIMINALAPPEALS 

### APR 16 2015 Abel Acosta, Clerk

:-'S i'i i—23PSC3 1^ j&PR.'201S .PM :W> I 

## R Be* I/Z308 Aus-frn ,Tx,

_ ' 761U-2*0* |W||||>|l|HII|-.i.|i.j.l|.|ll1.l..,,.1|lll1|.:,jl.i,,.||.].l.-. 

### O^RECEIVED IN COURT OF CRIMINALAPPCM 

### APR 16 2015 Abel Acosta, Clei.
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
STATEMENTS OF INCOME AND BALANCE SHEETS AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000,000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               JUN-30-1999
<CASH>                                              56
<SECURITIES>                                         0
<RECEIVABLES>                                      363
<ALLOWANCES>                                       180
<INVENTORY>                                         39
<CURRENT-ASSETS>                                   378
<PP&E>                                           1,486
<DEPRECIATION>                                     711
<TOTAL-ASSETS>                                   1,496
<CURRENT-LIABILITIES>                              236
<BONDS>                                            669
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                         571
<TOTAL-LIABILITY-AND-EQUITY>                     1,496
<SALES>                                              0
<TOTAL-REVENUES>                                   708
<CGS>                                                0
<TOTAL-COSTS>                                      407
<OTHER-EXPENSES>                                   161
<LOSS-PROVISION>                                    68
<INTEREST-EXPENSE>                                  33
<INCOME-PRETAX>                                    (63)
<INCOME-TAX>                                        18
<INCOME-CONTINUING>                                (45)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       (45)
<EPS-BASIC>                                      (1.51)
<EPS-DILUTED>                                    (1.51)


</TABLE>